Case 1 History. William Tremaine, M.D. CP

Size: px
Start display at page:

Download "Case 1 History. William Tremaine, M.D. CP"

Transcription

1 Extraintestinal Manifestations of IBD Case Studies William Tremaine, M.D. Case 1 History 18 year-old woman with Crohn s disease Onset at age 5: colonic & perianal Sulfasalazine, prednisone, mercaptopurine Long strictures: rectum and transverse colon Age 16 Proctocolectomy with ileostomy Age 17 Peristomal pyoderma gangrenosum CP

2 Case 1 History (continued) Age 18 Worsening pyoderma despite: Mercaptopurine, Infliximab Hughes AP. JAMA 2000;284:

3 Peristomal Pyoderma Gangrenosum Peristomal Pyoderma Gangrenosum Treatment options? 3

4 Conditions Associated with PG Crohn s disease Ulcerative colitis Chronic hepatitis Rheumatoid arthritis AML and CML Polycythemia vera Myeloma 30% to 50% may be idiopathic Demographics of PPG UC Crohn's Diverticulitis Adenoca Neurogenic Bladder Perforated bowel Lyon et al. J Am Acad Dermatol 2000:42:992 4

5 Demographics of PPG Annual incidence estimated at 0.6 per 100 ostomies 1 Time to onset after surgery 2 months to 25 years 2 1 Lyon et al. J Am Acad Dermatol 2000:42:992 Diagnosis of PPG Inflammatory disease in most Painful pink/purple papule Painful ulceration Raised purple edge Strands of persisting epidermis stretch across the ulcer Involves the area covered by the stoma bag adhesive plate 2 Hughes AP et al. JAMA 2000:284:1546 Lyon et al. J Am Acad Dermatol 2000:42:992 5

6 Diagnosis of PG: Rule out other causes of persistent ulcers Vascular occlusive or venous disease Antiphospholipid antibody syndrome Vasculitis Wegner s granulomatosis, Polyarteritis nodosum Lymphoma Deep fungal infection Exogenous tissue injury Munchausen s syndrome Cutaneous Crohn s disease Weenig et al. N Eng J Med 2002:347:1412 Common Misdiagnoses in PPG Stitch abscess Contact dermatitis Irritation from leakage of feces or urine Extension of underlying Crohn s disease Wound infection Hughes AP et al. JAMA 2000:284:1546 6

7 Diagnostic Tests Rule out other conditions Laboratory investigations None are pathognomonic Protein electrophoresis, CBC, coagulation panel, antiphospholipid antibody panel, cryoglobulins, vasculitis screen Biopsy No pathognomonic characteristics 46 of 86 (53%) of misdiagnosed patients in Mayo series had correct diagnosis evident on biopsy Therapy of PPG Current knowledge of therapy based on case series No RCTs Observational studies uniformly lack a control group Weenig et al. N Eng J Med 2002:347:1412 7

8 Systemic Agents Reported Possibly Effective in PG Corticosteroids Minocycline Dapsone Cyclosporine Tacrolimus Clofazamine Cyclophosphamide Melphalan Chlorambucil Powel et al. Dermatol Clin 2002:20:347 Azathioprine Methotrexate Interferon-α Potassium iodide Thalidomide Infliximab Adalimumab Mycophenolate mofetil Colchicine Medications for Severe PG Tacrolimus Cyclosporine Infliximab Cyclophosphamide Poritz LS. J Am Coll Surg 2008; 206: Alkhouri N. Inflam Bowel Dis (6):

9 Topical Tacrolimus for PPG Topical tacrolimus - 7 of 11 healed in mean 5.1 weeks vs. Topical steroids - 5 of 13 healed in mean 6.5 weeks Topical tacrolimus superior for large lesions (> 2cm in diameter) Lyon CC et al. J Dermatol Treatment 2001;12:13 IV Cyclosporine Mt Sinai 11 patients with steroid-refractory PG All healed with IV CSA followed by oral CSA Mean time to response 4.5 days Mean time to healed 1.4 months 9 of 11 discontinued steroids and were maintained on AZA/6-MP Friedman S et al. Inflammatory Bowel Disease 2001;7:1 9

10 Anti-TNFα Therapy for PG Relatively few reports Eight patients with PG and active CD 3 patients with complete healing and maintenance of healing 3 patients with partial healing or complete healing but relapse and intolerance to infliximab 2 patients without healing Response may depend on healing underlying CD but insufficient data to know for certain Ljung T et al. Scand J Gastroenterol 2002:37:1108 Cyclophosphamide for PG First reported in 1967 Pulse Cyclophosphamide first reported in 1994 Rapid healing and prolonged improvement in 2 patients with RA Additional data needed given recent evidence of effectiveness in CD Crawford SE et al. J pediatrics 1967:71:255 Zonana-Nacach A et al. J Rheumatol 1994:21:

11 Peristomal Pyoderma Summary Rule out other diagnoses Initial therapy with topical corticosteroids for small lesions and high dose corticosteroids or topical tacrolimus for large lesions Second line therapies include CSA, TAC, topical TAC, infliximab, other immunomodifiers, dapsone Comparative trials of therapies greatly needed Dermatological Manifestations Pyoderma gangrenosum 1-10% Erythema nodosum 1-10% Cutaneous Crohn s disease (rare) Psoriasis (up to 10%) Uncommon disorders Sweet s syndrome Epidermolysis bullosa acquisita 11

12 Erythema Nodosum More common in Crohn s (up to 15%), less in UC (up to 5%) Young women at most risk Painful tender erythematous nodules: pretibial, or areas of trauma Correlates with IBD activity Treat underlying IBD SKIN LESIONS Erythema Nodosum 12

13 Cutaneous Crohn s Disease Granulomatous lesions of skin Most common in perianal areas (e.g. tags) Metastatic Crohn s May not correlate with disease activity Steroids, immunosuppressives Case 2 Corneal Erosions 24 year old man Crohn s disease since age 18 Ileocolonic and perianal involvement Adalimumab weekly Nocturnal corneal erosions, recurrent Awakens with eye pain, dryness Rx: punctal plugs. Fell out. 13

14 Case 2 Corneal Erosions Case 2 Corneal Erosions (continued) Rx: punctal cautery, bilateral Still nocturnal awakening with burning eyes vaporizer, ointment, tetracaine Repeat trips to the ER for eye pain Stromal puncture, left eye 23-gauge needle, 200 corneal nicks Polytrim solution and erythromycin ointment: improved Right eye treatment: improved 14

15 Ocular Complications: Uveitis Inflammation of anterior chamber Prevalence 5% Ocular pain, redness, photophobia Slit lamp exam necessary for diagnosis Acute form associated with HLA B27 Chronic form not associated Treatment: Topical steroids, cycloplegic agents Oral steroids for refractory cases Immunosuppressives and anti-tnf agents Anterior Uveitis 15

16 Other Ocular Complications Episcleritis Episcleritis Outer layers of eye Eye burning or itching, erythema Activity correlates to IBD activity Topical corticosteroids Scleritis: more serious, oral steroids Retinitis: less common Cataracts, glaucoma due to steroids 16

Management of Pyoderma Gangrenosum Mentoring in IBD XVII

Management of Pyoderma Gangrenosum Mentoring in IBD XVII Management of Pyoderma Gangrenosum Mentoring in IBD XVII Scott Walsh MD PhD FRCPC Division of Dermatology Sunnybrook Health Sciences Centre University of Toronto Pyoderma Gangrenosum: A pathological

More information

ExtraintestinalManifestations of IBD

ExtraintestinalManifestations of IBD ExtraintestinalManifestations of IBD Hyun Kim, M.D. San Diego Digestive Disease Consultants Associate Professor, UCSD School of Medicine Why Other Organs Involved in IBD? Organ Involvement Bones, Joints

More information

More Non-infectious Granulomatous Diseases! Karolyn Wanat, MD Assistant Professor, Dermatology & Pathology University of Iowa

More Non-infectious Granulomatous Diseases! Karolyn Wanat, MD Assistant Professor, Dermatology & Pathology University of Iowa More Non-infectious Granulomatous Diseases! Karolyn Wanat, MD Assistant Professor, Dermatology & Pathology University of Iowa Conflicts of Interest/Disclosure None Classification/Overview 1) Necrobiotic/Palisading

More information

Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease

Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease Robert Isfort, M.D. TriHealth Digestive Institute IBD Family Education Day 2019 Learning Objectives Review manifestations

More information

SURGICAL MANAGEMENT OF ULCERATIVE COLITIS

SURGICAL MANAGEMENT OF ULCERATIVE COLITIS SURGICAL MANAGEMENT OF ULCERATIVE COLITIS Cary B. Aarons, MD Associate Professor of Surgery Division of Colon & Rectal Surgery University of Pennsylvania AGENDA Background Diagnosis/Work-up Medical Management

More information

Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG

Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.

More information

Crohn s Disease. Resident Lecture 1/17/19

Crohn s Disease. Resident Lecture 1/17/19 Crohn s Disease Resident Lecture 1/17/19 Objectives Features/Classification of Crohn s Disease Medical Treatment Surgical Indications Surgical Considerations 2 Case 25 yo F presents to your office with

More information

Topical Tacrolimus for Parastomal Pyoderma Gangrenosum: A Report of Two Cases

Topical Tacrolimus for Parastomal Pyoderma Gangrenosum: A Report of Two Cases Topical Tacrolimus for Parastomal Pyoderma Gangrenosum: A Report of Two Cases Maria Altieri, MS; Khashayar Vaziri, MD; and Bruce A. Orkin, MD Abstract Pyoderma gangrenosum (PG) is an idiopathic, ulcerative,

More information

INFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic

INFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic INFLAMMATORY BOWEL DISEASE Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic WHAT IS INFLAMMATORY BOWEL DISEASE (IBD)? Chronic inflammation of the intestinal tract Two related

More information

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight

More information

IBD in teenagers Biological and Transition

IBD in teenagers Biological and Transition IBD in teenagers Biological and Transition Dr Warren Hyer Consultant Paediatric Gastroenterologist St Mark s Hospital Chelsea and Westminster Hospital Conflict of Interest None to declare Fee for presentation

More information

PEDIATRIC INFLAMMATORY BOWEL DISEASE

PEDIATRIC INFLAMMATORY BOWEL DISEASE PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease

More information

Pharmacy Prior Authorization

Pharmacy Prior Authorization Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Index. Surg Clin N Am 87 (2007) Note: Page numbers of article titles are in boldface type.

Index. Surg Clin N Am 87 (2007) Note: Page numbers of article titles are in boldface type. Surg Clin N Am 87 (2007) 787 796 Index Note: Page numbers of article titles are in boldface type. A Abscesses in anorectal Crohn s disease, 622 intra-abdominal, in Crohn s disease, 590 591 perirectal,

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease

More information

The Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.

The Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D. The Spectrum of IBD Inflammatory Bowel Disease Fernando Vega, M.D. Epidemiology CD and UC together 1:400 UC Prevalence 1:500 UC Incidence 6-12K/annum CD Prevalence 1:1000 CD Incidence 3-6K/annum Symptoms

More information

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel

More information

The ABCs of Inflammatory Bowel Disease. Jennifer Choi, M.D. Associate Director March 31, 2012

The ABCs of Inflammatory Bowel Disease. Jennifer Choi, M.D. Associate Director March 31, 2012 The ABCs of Inflammatory Bowel Disease Jennifer Choi, M.D. Associate Director March 31, 2012 What Will This Talk Cover? What is IBD? What causes it? What are complications of it? How do I find out if I

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,

More information

Surgical Management of IBD. Val Jefford Grand Rounds October 14, 2003

Surgical Management of IBD. Val Jefford Grand Rounds October 14, 2003 Surgical Management of IBD Val Jefford Grand Rounds October 14, 2003 Introduction Important Features Clinical Presentation Evaluation Medical Treatment Surgical Treatment Cases Overview Introduction Two

More information

Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center

Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center CROHN S DISEASE Patchy inflammation Mouth to anus involvement Full-thickness inflammation Variable involvement

More information

Pyoderma gangrenosum presenting with acute generalised haemorrhagic bullae

Pyoderma gangrenosum presenting with acute generalised haemorrhagic bullae H.K. Dermatol. Venereol. Bull. (2003) 11, 155-159 Case Report Pyoderma gangrenosum presenting with acute generalised haemorrhagic bullae YH Chan, WYM Tang, WY Lam A 31-year-old Chinese man presented with

More information

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:

More information

CASE REPORT ATYPICAL BULLOUS PYODERMA GANGRENOSUM WITH EARLY LESIONS MIMICKING CHICKEN POX

CASE REPORT ATYPICAL BULLOUS PYODERMA GANGRENOSUM WITH EARLY LESIONS MIMICKING CHICKEN POX ATYPICAL BULLOUS PYODERMA GANGRENOSUM WITH EARLY LESIONS MIMICKING CHICKEN POX Ramesh M 1, Kavya Raju Nayak 2, M.G. Gopal 3, Sharath Kumar B.C 4, Nandini A.S 5 HOW TO CITE THIS ARTICLE: Ramesh M, Kavya

More information

C. Assess clinical response after the first three months of treatment.

C. Assess clinical response after the first three months of treatment. Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit

More information

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features

More information

Pharmacy Prior Authorization

Pharmacy Prior Authorization Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax

More information

Epidemiology / Morbidity

Epidemiology / Morbidity Perianal Crohn s Disease: Current Treatment Approach David A Schwartz, MD Director, Inflammatory Bowel Disease Center Vanderbilt University Medical Center Epidemiology / Morbidity Hellers et al, Gut 1980

More information

ULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC

ULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC ULCERATIVE COLITIS Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC What is Ulcerative Colitis? Ulcerative colitis (UC) is a disease marked by inflammation

More information

Slide 1 Medications in inflammatory bowel disease a primer for health care providers. Slide 2. Slide 3 Theory of pathogenesis. IBD - epidemiology

Slide 1 Medications in inflammatory bowel disease a primer for health care providers. Slide 2. Slide 3 Theory of pathogenesis. IBD - epidemiology Slide 1 Medications in inflammatory bowel disease a primer for health care providers Athos Bousvaros, MD Associate director Inflammatory Bowel Disease Center Boston Children s Hospital 617 355 2962 Slide

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Ulcerative colitis: the management of ulcerative colitis Quality standard title: Ulcerative

More information

PIBD03 - Page 1 of June-03

PIBD03 - Page 1 of June-03 ENROLLMENT INFO Patient Demographics [enroll01] Date of assessment [e_assessdt] 1. Patient birthdate: [birthdt] 2a. Month of diagnosis (please enter the 2-digit month) [e_diagmnth] 2b. Year of diagnosis

More information

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014 Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn

More information

Scleritis LEN V KOH OD

Scleritis LEN V KOH OD Scleritis LEN V KOH OD 2014 PUCO 1 Introduction A painful, destructive, and potentially blinding disorder Highly symptomatic High association with systemic disease Immunosuppresssive agents 2014 PUCO 2

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:

More information

Recognizing Pyoderma Gangrenosum in a Patient with History of Essential Thrombocytosis

Recognizing Pyoderma Gangrenosum in a Patient with History of Essential Thrombocytosis Open Journal of Clinical & Medical Case Reports Volume 2 (2016) Issue 17 ISSN 2379-1039 Recognizing Pyoderma Gangrenosum in a Patient with History of Essential Thrombocytosis * Amier Ahmad, Md ; Kevin

More information

Infliximab: A Treatment Option for Ulcerative Pyoderma Gangrenosum

Infliximab: A Treatment Option for Ulcerative Pyoderma Gangrenosum To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/449955 Infliximab: A Treatment Option for Ulcerative Pyoderma Gangrenosum

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,

More information

What Will This Talk Cover? 101: The Basics of Inflammatory Bowel Disease. Terms & Abbreviations. What Is Normal GI Anatomy?

What Will This Talk Cover? 101: The Basics of Inflammatory Bowel Disease. Terms & Abbreviations. What Is Normal GI Anatomy? 101: The Basics of Inflammatory Bowel Disease What Will This Talk Cover? What is IBD? What causes it? What are complications of it? How do I find out if I have IBD? How do we treat IBD? Jennifer Choi,

More information

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review

More information

Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children

Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children Stephanie Jones, D.O. Surgical Fellow March 21, 2011 Ulcerative Colitis Spectrum of inflammatory bowel

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1041-8 Program Prior Authorization/Notification Medication Humira (adalimumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,

More information

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel

More information

Moderately to severely active ulcerative colitis

Moderately to severely active ulcerative colitis Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients

More information

My Child Has Inflammatory Bowel Disease : Why? What now? What s next?

My Child Has Inflammatory Bowel Disease : Why? What now? What s next? My Child Has Inflammatory Bowel Disease : Why? What now? What s next? George M. Zacur, M.D., M.S. Clinical Assistant Professor Department of Pediatrics and Communicable Diseases Division of Gastroenterology

More information

Amjevita (adalimumab-atto)

Amjevita (adalimumab-atto) *- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled

More information

Medical therapies and IBD

Medical therapies and IBD Medical therapies and IBD Although there is no cure for IBD, there are many treatment options available. There is no standard treatment for IBD that is effective in all situations or for all patients,

More information

THE TIP OF THE ICEBERG SAMER BOLIS, DO PGY-3 LEHIGH VALLEY HEALTH NETWORK, ALLENTOWN PA

THE TIP OF THE ICEBERG SAMER BOLIS, DO PGY-3 LEHIGH VALLEY HEALTH NETWORK, ALLENTOWN PA THE TIP OF THE ICEBERG SAMER BOLIS, DO PGY-3 LEHIGH VALLEY HEALTH NETWORK, ALLENTOWN PA Case The patient is a 48 year-old female, who recently returned from a trip to Puerto Rico. She presents to the ED

More information

First Name. Specialty: Fax. First Name DOB: Duration:

First Name. Specialty: Fax. First Name DOB: Duration: Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:

More information

RHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center

RHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases

More information

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly

More information

Selby Inflamm Bowel Dis. 2008:14:

Selby Inflamm Bowel Dis. 2008:14: Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory

More information

Regional vs. Systemic Therapy. Corticosteroids. Regional vs. Systemic Therapy for Uveitis. Considerations

Regional vs. Systemic Therapy. Corticosteroids. Regional vs. Systemic Therapy for Uveitis. Considerations Regional vs. Systemic Therapy for Uveitis Nisha Acharya,, M.D., M.S. Director, Uveitis Service F.I. Proctor Foundation University of California, San Francisco December 4, 2010 No financial disclosures

More information

Inflammatory Bowel Disease: Updates and Controversies CASE #1 CASE #1 8/6/2015. What is the most likely diagnosis?

Inflammatory Bowel Disease: Updates and Controversies CASE #1 CASE #1 8/6/2015. What is the most likely diagnosis? Inflammatory Bowel Disease: Updates and Controversies Tehttp://192.185.93.102/~paulkeij/wpcontent/uploads/2013/07/collaboration.jpgxt August 7, 2015 Meagan M Costedio, MD; Colorectal Surgery; Cleveland

More information

Management of the Hospitalized IBD Patient. Drew DuPont MD

Management of the Hospitalized IBD Patient. Drew DuPont MD Management of the Hospitalized IBD Patient Drew DuPont MD Ulcerative Colitis: Indications for Admission Severe ulcerative colitis Frequent loose bloody stools ( 6 per day) Severe cramps Systemic toxicity:

More information

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10 Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality

More information

Coverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication

Coverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP

More information

Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic

Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification

More information

Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13

Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13 Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship

More information

Positioning Biologics in Ulcerative Colitis

Positioning Biologics in Ulcerative Colitis Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies

More information

Prevalence, risk factors and response to treatment of extra-intestinal manifestations in patients with inflammatory bowel disease

Prevalence, risk factors and response to treatment of extra-intestinal manifestations in patients with inflammatory bowel disease 1130-0108/2017/109/9/627-633 Revista Española de Enfermedades Digestivas Copyright 2017. SEPD y ARÁN EDICIONES, S.L. Rev Esp Enferm Dig 2017, Vol. 109, N.º 9, pp. 627-633 ORIGINAL PAPERS Prevalence, risk

More information

Speaker Introduction

Speaker Introduction Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University

More information

Chronic Granulomatous Disease Managing GI Issues

Chronic Granulomatous Disease Managing GI Issues Chronic Granulomatous Disease Managing GI Issues N I C H O L A S H A R T O G, M D D i r e c t o r o f P e d i a t r i c / A d u l t P r i m a r y I m m u n o d e f i c i e n c y C l i n i c A s s i s t

More information

Surgical Therapies for the Treatment of IBD!

Surgical Therapies for the Treatment of IBD! Surgical Therapies for the Treatment of IBD! Andrew A Shelton, MD Clinical Professor of Surgery Stanford Hospital and Clinics Section of Colon and Rectal Surgery! Ulcerative Colitis v. Crohn s! 30% of

More information

Percent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =

Percent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N = Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence

More information

Title: Prevalence, risk factors and response to treatment of extra-intestinal manifestations in patients with inflammatory bowel disease

Title: Prevalence, risk factors and response to treatment of extra-intestinal manifestations in patients with inflammatory bowel disease Title: Prevalence, risk factors and response to treatment of extra-intestinal manifestations in patients with inflammatory bowel disease Authors: María Hernández-Tejero, Alicia Granja Navacerrada, Pilar

More information

Adalimumab Therapy for Recalcitrant Pyoderma Gangrenosum

Adalimumab Therapy for Recalcitrant Pyoderma Gangrenosum Adalimumab Therapy for Recalcitrant Pyoderma Gangrenosum Margaret A. Fonder, BS, Deborah L. Cummins, MD, Benjamin D Ehst, MD, PhD, Grant J. Anhalt, MD, and Jon H. Meyerle, MD From the Department of Dermatology,

More information

APPLICATION FOR SPECIAL AUTHORITY. Subsidy for Infliximab

APPLICATION FOR SPECIAL AUTHORITY. Subsidy for Infliximab APPLICATION FOR SPECIAL AUTHORITY Fm SA1778 Subsidy f Infliximab Application Categy Page Graft vs host disease - Initial application... 2 Pulmonary sarcoidosis - Initial application... 2 Previous use -

More information

3. Has the patient shown improvement in signs and symptoms of the disease? Y N

3. Has the patient shown improvement in signs and symptoms of the disease? Y N Pharmacy Prior Authorization MERC CARE (MEDICAID) Renflexis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax

More information

Understanding Inflammatory Bowel Diseases (IBD):

Understanding Inflammatory Bowel Diseases (IBD): Understanding Inflammatory Bowel Diseases (IBD): What Every Patient Needs to Know William H Holderman, MD Digestive Health Specialists Tacoma, WA Today s Objectives Define IBD, its potential causes and

More information

2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N

2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N Pharmacy Prior Authorization AETA BETTER HEALTH LOUISIAA (MEDICAID) Remicade (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign

More information

Evolving therapies for posterior uveitis. Infliximab (Remicade) Infliximab: pharmacology. FDA-approved monoclonal antibody therapy Target

Evolving therapies for posterior uveitis. Infliximab (Remicade) Infliximab: pharmacology. FDA-approved monoclonal antibody therapy Target Evolving therapies for posterior uveitis Sam Dahr, M.D. September 17, 2005 Midwest Ophthalmology Conference Infliximab (Remicade) FDA approved for Crohn s disease, rheumatoid arthritis, and psoriatic arthritis

More information

Crohn's Disease. The What, When, and Why of Treatment

Crohn's Disease. The What, When, and Why of Treatment Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University

More information

Inflammatory Bowel Disease

Inflammatory Bowel Disease Inflammatory Bowel Disease William Sonnenberg, MD Titusville, PA Disclosure Dr. William Sonnenberg has no conflict of interest, financial agreement, or working affiliation with any group or organization.

More information

Crohn's Disease. The What, When, and Why of Treatment

Crohn's Disease. The What, When, and Why of Treatment Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be

More information

Case 1. Debridement Cultures Keflex Silvadene

Case 1. Debridement Cultures Keflex Silvadene The Red Breast Beth McLellan, M.D. Assistant Professor Division of Dermatology Albert Einstein College of Medicine Montefiore Medical Center Jacobi Medical Center Case 1 48 year old radiation oncologist

More information

September 12, 2015 Millie D. Long MD, MPH, FACG

September 12, 2015 Millie D. Long MD, MPH, FACG Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn

More information

Superficial Granulomatous Pyoderma of the Face: A Case Report and Review of the Literature

Superficial Granulomatous Pyoderma of the Face: A Case Report and Review of the Literature Superficial Granulomatous Pyoderma of the Face: A Case Report and Review of the Literature Sarah M. Persing, MPH, a and Donald Laub Jr, MD, FACS a,b a University of Vermont College of Medicine, Burlington;

More information

Ali Keshavarzian MD Rush University Medical Center

Ali Keshavarzian MD Rush University Medical Center Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting

More information

Dr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)

Dr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest) EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions

More information

Behçet s Disease: The American Perspectivecan Pers. Disclosures. Learning Objectives 4/16/2018

Behçet s Disease: The American Perspectivecan Pers. Disclosures. Learning Objectives 4/16/2018 Behçet s Disease: The American Perspectivecan Pers Cailin Sibley, M.D., M.H.S. Director, Vasculitis Clinic April 27 th, 2018 NTEREST DISCLOSURE Disclosures As no medications to treat Behçet s disease are

More information

Humira (adalimumab) DRUG.00002

Humira (adalimumab) DRUG.00002 Humira (adalimumab) DRUG.00002 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Humira 10 mg/0.2 ml syringe Humira pediatric Crohn s Disease starter pack 40 mg/0.8 ml

More information

Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form Submit request via: Fax

Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form  Submit request via: Fax Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Humira (adalimumab) require a prior

More information

Diarrhoea for the Acute Physician

Diarrhoea for the Acute Physician Diarrhoea for the Acute Physician STEPHEN INNS GASTROENTEROLOGIST AND PHYSICIAN HUTT VALLEY DHB August 2013 Outline Case History 1 Initial assessment of acute diarrhoea Management of fulminant UC Management

More information

Skin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France

Skin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France Skin cancers in patients treated with immunomodulating drugs Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France Immunomodulating drugs used in Methotrexate Mycophenolate

More information

Remicade (infliximab) DRUG.00002

Remicade (infliximab) DRUG.00002 Applicability/Effective Date *- Florida Healthy Kids Remicade (infliximab) DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Approval Duration 1 year Comment Intravenous

More information

Regulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Regulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 10 Last Review Date: June 22, 2017 Humira Description Humira (adalimumab),

More information

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N 12/21/2016 Prior Authorization Aetna Better Health of West Virginia Humira (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and

More information

1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.

1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits. Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically

More information

Frequency of pathergy phenomenon and other features of Behçet s syndrome among patients with inflammatory bowel disease

Frequency of pathergy phenomenon and other features of Behçet s syndrome among patients with inflammatory bowel disease Frequency of pathergy phenomenon and other features of Behçet s syndrome among patients with inflammatory bowel disease I. Hatemi 1, G. Hatemi 2, A. F. Celik 1, M. Melikoglu 2, N. Arzuhal 3, C. Mat 3,

More information

Inflectra Frequently Asked Questions

Inflectra Frequently Asked Questions Inflectra Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Earlier in 2016, Inflectra (infliximab) was added to the Ontario Drug Benefit (ODB) Formulary as a Limited

More information

Indications for use of Infliximab

Indications for use of Infliximab Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of

More information

Colostomy & Ileostomy

Colostomy & Ileostomy Colostomy & Ileostomy Indications, problems and preference By Waleed Omar Professor of Colorectal surgery, Mansoura University. Disclosure I have no disclosures. Presentation outline Stoma: Definition

More information

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I

More information

Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)

Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) DRUG POLICY BENEFIT APPLICATION Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Benefit determinations are based on the applicable contract language in effect at the time

More information

Medical Therapy for Pediatric IBD: Efficacy and Safety

Medical Therapy for Pediatric IBD: Efficacy and Safety Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission

More information

Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online Support Group.

Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online Support Group. Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online. Last week s material consisted of an overview of inflammatory bowel diseases (IBD), specifically Crohn s disease and ulcerative

More information

Cutaneous Manifestations in Inflammatory Bowel Diseases

Cutaneous Manifestations in Inflammatory Bowel Diseases Journal of Mind and Medical Sciences Volume 2 Issue 2 Article 2 2015 Cutaneous Manifestations in Inflammatory Bowel Diseases Simona Roxana Georgescu Carol Davila University of Medicine and Pharmacy, simonaroxanageorgescu@yahoo.com

More information

Fistulizing Crohn s Disease: The Aggressive Approach

Fistulizing Crohn s Disease: The Aggressive Approach Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary

More information

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

CCFA. Crohns Disease vs UC: What is the best treatment for me? November CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York

More information